Bardoxolone methyl - AbbVie/Kyowa Hakko Kirin/Reata Pharmaceuticals

Drug Profile

Bardoxolone methyl - AbbVie/Kyowa Hakko Kirin/Reata Pharmaceuticals

Alternative Names: Bard - Reata Pharmaceuticals; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Kyowa Hakko Kirin; Reata Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antihypertensives; Antineoplastics; Small molecules; Triterpenes
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Hereditary nephritis; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic nephropathies; Hereditary nephritis; Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Renal failure
  • Discontinued Haematological malignancies; Malignant melanoma; Non-alcoholic steatohepatitis; Pancreatic cancer; Solid tumours; Viral hepatitis

Most Recent Events

  • 31 May 2018 Phase-III clinical trials in Diabetic nephropathies in Japan (PO) (JapicCTI183955)
  • 31 May 2018 Bardoxolone methyl - AbbVie/Kyowa Hakko Kirin/Reata Pharmaceuticals receives Orphan Drug status for Hereditary nephritis in European Union
  • 25 May 2018 Safety and efficacy data from the phase II PHOENIX trial in Renal failure released by Reata Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top